{
    "clinical_study": {
        "@rank": "139597", 
        "acronym": "IriGen", 
        "arm_group": {
            "arm_group_label": "irinotecan dose based on genetic polymorphism of UGT1A1", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This prospective, non randomized multicenter phase II study, will determine the feasibility\n      of individualized dose of irinotecan with the UGT1A1 polymorphism, in patients with\n      metastatic colorectal cancer treated with FOLFIRI."
        }, 
        "brief_title": "Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "First Line Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Colorectal cancer histologically or cytologically proven\n\n          -  Indication of treatment according to the FOLFIRI + / - bevacizumab\n\n          -  Age> 18 years\n\n          -  Presence of at least one measurable target by RECIST\n\n          -  Life expectancy> 3 months\n\n          -  Satisfactory biological functions (renal, hepatic and hematologic)\n\n          -  Affiliation to a social security scheme (or be the beneficiary of such a plan) under\n             the terms of the Act of August 9, 2004\n\n          -  Patient has signed, after informing the informed consent form\n\n        Exclusion Criteria:\n\n          -  Patients of childbearing age and not using effective contraception during treatment\n             and for at least three months after the end of treatment with irinotecan and at least\n             six months after the end of treatment with bevacizumab and patient pregnant or\n             nursing\n\n          -  Patient with another pathology deemed incompatible with the entry in the protocol\n\n          -  Prior treatment in metastatic\n\n          -  Patients taking antiepileptic\n\n          -  Allergic reaction or intolerance to irinotecan\n\n          -  Heart failure , kidney , bone marrow , liver or respiratory\n\n          -  Higher bilirubin 1.5 times the upper limit of normal\n\n          -  Significant psychiatric or neurological abnormality\n\n          -  Infectious syndrome requiring treatment with antibiotics or antiviral long-term\n\n          -  Patients with chronic inflammatory bowel disease and / or bowel obstruction\n\n          -  Contraindication Association St. John's wort and yellow fever vaccine\n\n          -  Against Heart indication 5-FU\n\n          -  Concurrent treatment with a drug test , participation in a clinical trial within <30\n             days\n\n          -  Patient refused to sign the consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963182", 
            "org_study_id": "2013-001275-21"
        }, 
        "intervention": {
            "arm_group_label": "irinotecan dose based on genetic polymorphism of UGT1A1", 
            "intervention_name": "Irinotecan", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Irinotecan"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beaumont", 
                        "country": "France", 
                        "zip": "63110"
                    }, 
                    "name": "Clinique de la Ch\u00e2taigneraie"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "Xavier.DURANDO@cjp.fr", 
                    "last_name": "Xavier DURANDO, MD, PhD", 
                    "phone": "33473278103"
                }, 
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France", 
                        "zip": "63011"
                    }, 
                    "name": "Centre Jean Perrin"
                }, 
                "investigator": {
                    "last_name": "Xavier DURANDO, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cpetorin@chu-clermontferrand.fr", 
                    "last_name": "Caroline PETORIN, MD", 
                    "phone": "33473750508"
                }, 
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France", 
                        "zip": "63011"
                    }, 
                    "name": "CHU Estaing"
                }, 
                "investigator": {
                    "last_name": "Caroline PETORIN, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer", 
        "overall_contact": {
            "email": "pauline.herviou@cjp.fr", 
            "last_name": "Pauline HERVIOU", 
            "phone": "33463663358"
        }, 
        "overall_official": {
            "affiliation": "Centre Jean Perrin", 
            "last_name": "Xavier DURANDO, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "severe toxicity (according to NCI-CTC cotation) and response with adapted dose of irinotecan", 
            "safety_issue": "Yes", 
            "time_frame": "during the treatment (an expected average of 7 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963182"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Study of the blood concentration (pharmacokinetic) of irinotecan, the SN38 and SN38-G, and bevacizumab", 
                "safety_issue": "No", 
                "time_frame": "during the first 24 hours of the first cure"
            }, 
            {
                "measure": "evaluation of treatment efficacy (progression-free survival, duration of response)", 
                "safety_issue": "No", 
                "time_frame": "to progression (1 year)"
            }
        ], 
        "source": "Centre Jean Perrin", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Jean Perrin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}